A serious misprint appeared in the paper entitled, “Reducing Perinatal Transmission of HIV: Early Diagnosis and Interventions During Pregnancy,” by Elizabeth Stein, CNM, MSN, MPH, Edward Handelsman, MD, and Roland Matthews, MD, which was published in Volume 45, Number 2, pages 122–129 (March/April 2000) of the Journal of Midwifery & Women's Health (JMWH). In Table 2 on page 125, asterisks appeared after all of the Category C antiretroviral medications prescribed for HIV Infection, indicating that they were contraindicated in pregnancy. In fact, only Efavirenz (Sustiva) should have been labeled as such, even though it is still categorized as a Category C drug. The Table as it should have appeared is reprinted below. Sincere apologies are extended to the authors and to JMWH's readership.
|Generic Name||Brand/Trade Name||Pregnancy Category|
|FDA approved nucleoside reverse transcriptase inhibitors|
|Zidovudine||AZT, ZDV, Retrovir||C|
|Zidovudine 300 mg and lamivudine 150 mg (combined)||Combivir||C|
|FDA approved protease inhibitors|
|FDA approved non-nucleoside reverse transcriptase inhibitors|